Low‐ Versus High‐capacity Impella for CS After AMI: A Systematic Review and Pooled Data Analysis
- 8 January 2026
- journal article
- review article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (4) , 1246-1253
Abstract
Background: Acute myocardial infarction with cardiogenic shock (AMI‐CS) remains highly fatal despite advances in revascularization and intensive care. The Impella, a micro‐axial pump, offers a potential balance of hemodynamic support and minimal invasiveness. Aims: This study examined its optimal configuration of low‐ versus high‐capacity for effectiveness and safety. Methods: We conducted a systematic review and pooled analysis of 20 studies, including three randomized controlled trials (RCTs) and 3896 AMI‐CS patients, comparing high‐capacity (Impella 5.0/5.5) versus low‐capacity (Impella 2.5/CP) devices. The primary outcome was in‐hospital or 30‐day mortality, with secondary endpoints including mortality on support, ischemic and bleeding complications, acute kidney injury requiring renal replacement therapy (RRT), and hemolysis. Results: Among the included patients, 2022 received low‐capacity Impella, while 771 received high‐capacity Impella. The high‐capacity Impella group demonstrated lower in‐hospital or 30‐day mortality (41.4% vs. 45.4%; p = 0.045) and significantly reduced mortality on support (17.9% vs. 46.1%; p < 0.001). Major bleeding events (1.4% vs. 6.0%; p < 0.001) and ischemic complications (3.9% vs. 5.9%; p = 0.05) were also lower in the high‐capacity group. However, transfusion requirements were higher in the high‐capacity Impella cohort (52.1% vs. 23.1%; p < 0.001). There were no significant differences in stroke rates (4.3% vs. 4.3%; p = 1.0) or AKI requiring RRT (36.5% vs. 34.9%; p = 0.69). Conclusion: High‐capacity Impella, when compared to low‐capacity devices, may provide superior survival benefits and lower complication rates, particularly in reducing ischemic and major bleeding events, in AMI‐CS patients. These findings support the early consideration of high‐capacity Impella in treatment algorithms.Keywords
This publication has 34 references indexed in Scilit:
- Adverse events and failure modes related to Impella CP: Insights from the FDA MAUDE databaseCardiovascular Revascularization Medicine, 2025
- MI2AMI-CS: A meta-analysis comparing Impella and IABP outcomes in Acute Myocardial Infarction-related Cardiogenic ShockInternational Journal of Cardiology, 2024
- Clinical outcomes among cardiogenic shock patients supported with high-capacity Impella axial flow pumps: A report from the Cardiogenic Shock Working GroupThe Journal of Heart and Lung Transplantation, 2024
- Is there additional value in adding Impella to veno-arterial extracorporeal membrane oxygenation in patients with cardiogenic shock?Cardiovascular Revascularization Medicine, 2024
- Impella and Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock Complicating Acute Myocardial InfarctionEuropean Journal of Heart Failure, 2023
- Improved clinical outcomes associated with the Impella 5.5 compared to the Impella 5.0 in contemporary cardiogenic shock and heart failure patientsThe Journal of Heart and Lung Transplantation, 2023
- Short term outcomes of Impella in cardiogenic shock: A review and meta-analysis of observational studiesInternational Journal of Cardiology, 2021
- Impella percutaneous left ventricular assist device as mechanical circulatory support for cardiogenic shock: A retrospective analysis from a tertiary academic medical centerCatheterization and Cardiovascular Interventions, 2020
- Comparison of mechanical circulatory support with venoarterial extracorporeal membrane oxygenation or Impella for patients with cardiogenic shock: a propensity-matched analysisClinical Research in Cardiology, 2020
- SCAI clinical expert consensus statement on the classification of cardiogenic shockCatheterization and Cardiovascular Interventions, 2019